Overview Financials News + Filings Key Docs Charts Transactions Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
CC transcript
Credit agrmnt [a]
Appointed director
Inv. presentation
Quarterly results
Acq. announced
Director departure
|
|
Bausch Health Companies Inc. (BHC)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 09/29/2023 |
8-K
| Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financia...|
Docs:
|
"Indenture, by and among Bausch + Lomb Corporation, the guarantors party thereto and Citibank, N.A., acting through its agency and trust division, as trustee, and as notes collateral agent thereto",
"Credit Agreement, as amended by the First Incremental Amendment, by and among Bausch + Lomb Corporation, certain subsidiaries of Bausch + Lomb Corporation as subsidiary guarantors, the lenders party thereto, Citibank, N.A., as collateral agent thereto, Goldman Sachs Bank USA, as term facility administrative agent thereto and JPMorgan Chase Bank, N.A., as first incremental term facility administrative agent thereto",
"Bausch Health's Bausch + Lomb Announces Completion of the Acquisition of XIIDRA ® LAVAL, Quebec, September 29, 2023 - Bausch + Lomb Corporation , a subsidiary of Bausch Health Companies Inc. , today announced it has completed its acquisition of XIIDRA ® 5%, a non-steroid eye drop specifically approved to treat the signs and symptoms of dry eye disease focusing on inflammation associated with dry eye, and certain other ophthalmology assets. Under the terms of the agreement, Bausch + Lomb, through an affiliate, acquired XIIDRA ® and the other ophthalmology assets from Novartis for up to $2.5 billion, including an upfront payment of $1.75 billion in cash with potential milestone obligations of up to $750 million based on sales thresholds and pipeline commercialization. Bausch + Lomb also acqu..." |
|
| 09/29/2023 |
8-K/A
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 08/03/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 08/03/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/03/2023 |
8-K
| Quarterly results |
| 07/19/2023 |
SD
| Form SD - Specialized disclosure report: |
| 07/07/2023 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
| 07/07/2023 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...|
Docs:
|
"Credit and Security Agreement, by and among Bausch Receivables Funding LP, as Borrower, Bausch Receivables Funding GP ULC, Bausch Health US, LLC, as the Master Servicer, GLAS USA LLC, as Administrative Agent, GLAS Americas LLC, as Collateral Agent, KKR Capital Markets LLC, as Left Lead Arranger, KKR Credit Advisors (US) LLC, as Structuring Advisor, and the Lenders from time to time party thereto",
"Bausch Health Enters Into $600 Million Financing Facility With KKR LAVAL, Quebec, July 7, 2023 - Bausch Health Companies Inc. and KKR today announced that Bausch Receivables Funding LP, an Ontario limited partnership and wholly-owned subsidiary of Bausch Health, has entered into a $600 million non-recourse financing facility with KKR and its credit funds and accounts. The facility will be collateralized by certain accounts receivables originated by a wholly-owned subsidiary of Bausch Health. Bausch Health expects to utilize the proceeds from the facility for general corporate purposes. The facility provides access to additional liquidity for a term of approximately five years. Houlihan Lokey, Inc. acted as the Company's financial advisor. Finacity Corporation acted as the administrator for..." |
|
| 06/30/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"SECURITIES AND EXCHANGE COMMISSION",
"Bausch Health's Bausch + Lomb to Acquire Novartis' XIIDRA ® LAVAL, Quebec, June 30, 2023 - Bausch + Lomb Corporation , a subsidiary of Bausch Health Companies Inc. , announced that it has entered into a definitive agreement with Novartis to acquire XIIDRA ® 5%, a non-steroid eye drop specifically approved to treat the signs and symptoms of dry eye disease focusing on inflammation associated with dry eye. Under the terms of the agreement, Bausch + Lomb, through an affiliate, has agreed to acquire XIIDRA, libvatrep and AcuStream from Novartis for up to $2.5 billion, including an upfront payment of $1.75 billion in cash with potential milestone obligations up to $750 million based on sales thresholds and pipeline commercialization. Bausch + Lomb will also bring on the sales force supporting X..." |
|
| 05/17/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/04/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/04/2023 |
8-K
| Quarterly results |
| 04/06/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/06/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/06/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/06/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 03/01/2023 |
8-K
| Quarterly results |
| 02/23/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 02/14/2023 |
SC 13G
| Bausch Health Companies Inc. reports a 88.7% stake in Bausch + Lomb Corporation |
| 02/14/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/13/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 11/29/2022 |
8-K
| Quarterly results |
| 11/03/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/03/2022 |
8-K
| Quarterly results |
| 10/04/2022 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...|
Docs:
|
"Indenture, by and among Bausch Health Companies Inc., the guarantors party thereto, The Bank of New York Mellon, as trustee, and the notes collateral agents party thereto",
"Indenture, by and among Bausch Health Companies Inc., the guarantors party thereto, The Bank of New York Mellon, as trustee, and the notes collateral agents party thereto",
"Indenture, by and among 1375209 B.C. Ltd., The Bank of New York Mellon, as trustee, and The Bank of New York Mellon, as notes collateral agent" |
|
| 09/28/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 09/15/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 09/12/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 09/02/2022 |
10-Q/A
| Quarterly Report for the period ended June 30, 2022 [amend] |
| 08/31/2022 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 08/22/2022 |
8-K
| Quarterly results |
| 08/09/2022 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 08/09/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/09/2022 |
8-K
| Quarterly results |
|
|
|